Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Virology|October 17, 2006
Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approachSlavoljub Milosevic, Uta Behrends, Dinesh Adhikary, et al.
Journal of Immunological Methods|September 20, 2005
Direct mapping of MHC class II epitopesSlavoljub Milosevic, Uta Behrends, Heike Christoph, et al.
Oncoimmunology|June 22, 2012
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedureSusanne Wilde, Christiane Geiger, Slavoljub Milosevic, et al.
The Journal of Clinical Investigation|October 28, 2010
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptorsMatthias Leisegang, Susanne Wilde, Stefani Spranger, et al.
Transplantation|August 31, 2010
Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantationSlavoljub Milosevic, Barbara Bachnick, Karzan Karim, et al.
European Journal of Immunology|May 6, 2003
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagyFalk Nimmerjahn, Slavoljub Milosevic, Uta Behrends, et al.
European Journal of Immunology|August 13, 2004
Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cellsJosef Mautner, Dagmar Pich, Falk Nimmerjahn, et al.
Blood|July 10, 2009
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional aviditySusanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, et al.
Immunobiology|December 10, 2013
CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCTBrigitte Steger, Slavoljub Milosevic, Georg Doessinger, et al.
Blood|July 14, 2007
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignanciesIngrid G Schuster, Dirk H Busch, Elfriede Eppinger, et al.
Pageof 1